Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325889 | 0.88 | CHEK2 (0.40) | PARP1CHEK2NR1H2NR1H3PPARG | |
| SCHEMBL4316563 | 0.84 | PIK3CD (0.43) | PARP1CHEK2CDC7PLA2G2APLA2G10 | |
| SCHEMBL4331605 | 0.84 | PARP1 (0.40) | PARP1PLA2G2APLA2G10GRM2 | |
| SCHEMBL4325897 | 0.73 | LCK (0.42) | PARP1PLA2G2APLA2G10 | |
| SCHEMBL13571397 | 0.72 | CYP11B1 (0.51) | PARP1CDC7DHODH | |
| SCHEMBL23647305 | 0.70 | NOTUM (0.43) | PARP1PPARGCDC7PLA2G2APLA2G10 | |
| SCHEMBL4316571 | 0.69 | PIK3CD (0.43) | PARP1CDC7PLA2G2APLA2G10 | |
| SCHEMBL4331608 | 0.69 | PIK3CD (0.40) | CDC7GRM2 | |
| SCHEMBL28256484 | 0.69 | PLA2G2A (0.47) | PARP1PLA2G2APLA2G10CA1CA2 | |
| SCHEMBL27710607 | 0.68 | SIRT2 (0.43) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | PARP1 4537/4885CHEK2 3823/4885NR1H2 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.